Published online before print April 16, 2007, doi: 10.1161/CIRCULATIONAHA.106.676809
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;115:2331-2339.)
© 2007 American Heart Association, Inc.
Vascular Medicine |
Phosphodiesterase 1 Upregulation in Pulmonary Arterial Hypertension
Target for Reverse-Remodeling Therapy
From the University of Giessen Lung Centre (R.T.S., S.S.P., R.D., X.T., N.W., H.A.G., C.K., R.V., J.Z., A.S., W.S., F.G.), Giessen, Germany; Department of Pathology (G.K.) and Department of Anatomy and Cell Biology (R.P., W.K.), Justus Liebig University Giessen, Giessen, Germany; Department of Biochemistry 2 Inflammation (T.D., C.S.), Altana Pharma, Konstanz, Germany; and Department of Cardiothoracic Surgery (W.K.), University of Vienna, Vienna, Austria.
Correspondence to Ralph Schermuly, University of Giessen Lung Centre, Justus-Liebig-Universität Giessen, Klinikstrasse 36, 35392 Giessen, Germany. E-mail ralph.schermuly{at}uglc.de
Received November 16, 2006; accepted February 20, 2007.
Background— Pulmonary arterial hypertension (PAH) is a life-threatening disease, characterized by vascular smooth muscle cell hyperproliferation. The calcium/calmodulin-dependent phosphodiesterase 1 (PDE1) may play a major role in vascular smooth muscle cell proliferation.
Methods and Results— We investigated the expression of PDE1 in explanted lungs from idiopathic PAH patients and animal models of PAH and undertook therapeutic intervention studies in the animal models. Strong upregulation of PDE1C in pulmonary arterial vessels in the idiopathic PAH lungs compared with healthy donor lungs was noted on the mRNA level by laser-assisted vessel microdissection and on the protein level by immunohistochemistry. In chronically hypoxic mouse lungs and lungs from monocrotaline-injected rats, PDE1A upregulation was detected in the structurally remodeled arterial muscular layer. Long-term infusion of the PDE1 inhibitor 8-methoxymethyl 3-isobutyl-1-methylxanthine in hypoxic mice and monocrotaline-injected rats with fully established pulmonary hypertension reversed the pulmonary artery pressure elevation, structural remodeling of the lung vasculature (nonmuscularized versus partially muscularized versus fully muscularized small pulmonary arteries), and right heart hypertrophy.
Conclusions— Strong upregulation of the PDE1 family in pulmonary artery smooth muscle cells is noted in human idiopathic PAH lungs and lungs from animal models of PAH. Inhibition of PDE1 reverses structural lung vascular remodeling and right heart hypertrophy in 2 animal models. The PDE1 family may thus offer a new target for therapeutic intervention in pulmonary hypertension.
CLINICAL PERSPECTIVE
This article has been cited by other articles:
 |
|
 |
|
  I. P. Laumanns, L. Fink, J. Wilhelm, J.-C. Wolff, R. Mitnacht-Kraus, S. Graef-Hoechst, M. M. Stein, R. M. Bohle, W. Klepetko, M. A. R. Hoda, et al. The Noncanonical WNT Pathway Is Operative in Idiopathic Pulmonary Arterial Hypertension Am. J. Respir. Cell Mol. Biol., June 1, 2009; 40(6): 683 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Woyda, S. Koebrich, I. Reiss, S. Rudloff, S. S. Pullamsetti, A. Ruhlmann, N. Weissmann, H. A. Ghofrani, A. Gunther, W. Seeger, et al. Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia Eur. Respir. J., April 1, 2009; 33(4): 861 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schafer, P. Ellinghaus, W. Janssen, F. Kramer, K. Lustig, H. Milting, R. Kast, and M. Klein Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling Cardiovasc Res, April 1, 2009; 82(1): 30 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Beghetti and N. Galie Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J. Am. Coll. Cardiol., March 3, 2009; 53(9): 733 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-J. Lai, S. S. Pullamsetti, E. Dony, N. Weissmann, G. Butrous, G.-A. Banat, H. A. Ghofrani, W. Seeger, F. Grimminger, and R. T. Schermuly Role of the Prostanoid EP4 Receptor in Iloprost-mediated Vasodilatation in Pulmonary Hypertension Am. J. Respir. Crit. Care Med., July 15, 2008; 178(2): 188 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Wilkins, J. Wharton, F. Grimminger, and H. A. Ghofrani Phosphodiesterase inhibitors for the treatment of pulmonary hypertension Eur. Respir. J., July 1, 2008; 32(1): 198 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-C. Peyter, V. Muehlethaler, L. Liaudet, M. Marino, S. Di Bernardo, G. Diaceri, and J.-F. Tolsa Muscarinic receptor M1 and phosphodiesterase 1 are key determinants in pulmonary vascular dysfunction following perinatal hypoxia in mice Am J Physiol Lung Cell Mol Physiol, July 1, 2008; 295(1): L201 - L213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Klein, R. T. Schermuly, P. Ellinghaus, H. Milting, B. Riedl, H. A. Ghofrani, F. Grimminger, and S. Schafer Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure Eur. Respir. Rev., June 1, 2008; 17(108): 72 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kirsch, B. Kemp-Harper, N. Weissmann, F. Grimminger, and H. H. H. W. Schmidt Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signaling FASEB J, January 1, 2008; 22(1): 30 - 40. [Abstract] [Full Text] [PDF]
|
|